Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes

Bone Marrow Transplant. 2022 Sep;57(9):1461-1463. doi: 10.1038/s41409-022-01729-z. Epub 2022 Jun 22.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Aplastic* / therapy
  • Bone Marrow Transplantation
  • Decitabine / pharmacology
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Transplantation Conditioning / methods

Substances

  • Decitabine